Open AccessmiR‐495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression
Author(s) -
Zou Zhenyou,
Zou Ruyi,
Zong Dan,
Shi Yonghong,
Chen Jinyao,
Huang Jie,
Zhu Jiahui,
Chen Liguan,
Bao Xiaoyan,
Liu Yuan,
Liu Weihao,
Huang Wenhui,
Hu Jingsang,
Chen Zhi,
Lao Xiaojie,
Chen Chaoqun,
Huang Xiaoli,
Lu Yao,
Ni Xueyin,
Fang Daoquan,
Wu Dengqiang,
Lu Shuangshuang,
Jiang Mingzhu,
Qiu Chenyang,
Wu Yuya,
Qiu Qisha,
Dong Yanyuan,
Su Yangyang,
Zhao Chenmin,
Zhong Zhihe,
Cai Jing,
Liang Yong
Publication year - 2017
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13114
Subject(s) - doxorubicin , multiple drug resistance , cancer cell , cancer research , ovarian cancer , efflux , cancer , in vivo , biology , drug resistance , chemotherapy , drug , apoptosis , pharmacology , biochemistry , genetics , microbiology and biotechnology
MDR1 is highly expressed in MDR A2780DX5 ovarian cancer cells, MDR SGC7901R gastric cancer cells and recurrent tumours. It pumps cytoplasmic agents out of cells, leading to decreased drug accumulation in cells and making cancer cells susceptible to multidrug resistance. Here, we identified that miR‐495 was predicted to target ABCB1 , which encodes protein MDR1. To reduce the drug efflux and reverse MDR in cancer cells, we overexpressed a miR‐495 mimic in SGC7901R and A2780DX cells and in transplanted MDR ovarian tumours in vivo . The results indicated that the expression of MDR1 in the above cells or tumours was suppressed and that subsequently the drug accumulation in the MDR cells was decreased, cell death was increased, and tumour growth was inhibited after treatment with taxol‐doxorubicin, demonstrating increased drug sensitivity. This study suggests that pre‐treatment with miR‐495 before chemotherapy could improve the curative effect on MDR1‐based MDR cancer.